medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2014; 13 (2)


Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients

Campos-Varela I, Esteban JI, Bes M, Dopazo C, Allende H, Rodríguez-Frías F, Salcedo MT, Sauleda S, Charco R, Guardia J, Esteban R, Castells L

Idioma: Ingles.
Referencias bibliográficas: 38
Paginas: 219-230
Archivo PDF: 142.60 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-20.

  2. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14(Suppl. 2): S36-S44.

  3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.

  4. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, Córdoba J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-84.

  5. Berenguer M, Prieto M, Rayo’n JM, Mora J, Pastor M, Ortiz V, Carrasco D, et al. Natural history of clinically compensated HCV-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-8.

  6. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, Fiel I et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971-6.

  7. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, Radke C, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-6.

  8. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SNS, Lemonnier C, Cohard M, et al. Interferon-a 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-50.

  9. Neff GW, Montalbano M, O’Brien CB, Nishida S, Safdar K, Bejarano PA, Khaled AS, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 1303-7.

  10. Berenguer M, Charco R, Pascasio JM, Herrero JI. Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. Liver Int 2012; 32: 712-31.

  11. Carrion JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosh J, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-56.

  12. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.

  13. Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-87.

  14. Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodríguez M, Gentili F, Risalde B, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738-46.

  15. Castells L, Vargas V, Allende H, Bilbao I, Luis LJ, Margarit C, Esteban R, et al. Combined treatment with pegylated interferon (a-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53-9.

  16. Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007; 20: 583-90.

  17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP;STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7. Available from: www.strobe-statement.org

  18. Ishak K, Baptista A, Bianchi L, Callea F, De GJ, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.

  19. Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, Escartin A. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 2005; 18: 1336-45.

  20. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.

  21. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.

  22. Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero- Gómez M, Barroso N, Aguilar-Reina J, Núñez-Roldán A, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-7.

  23. Berenguer M, Aguilera V, Rubín A, Ortíz C, Jimenez M, Prieto M. Comparison of two non-contemporaneous HCVliver transplant cohorts: Strategies to improve the efficacy of antiviral therapy. J Hepatol 2012; 56: 1310-6.

  24. Samuel D. Hepatitis C, interferon, and risk of rejection after liver transplantation. Liver Transpl 2004; 10: 868-71.

  25. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, Farmer DG, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859-67.

  26. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.

  27. Bes M, Sauleda S, Campos-Varela I, Rodríguez-Frías F, Casamitjana N, Homs M, Piron M, et al. IL28B genetic variation and hepatitis C virus specific CD4 T cell response in anti-HCV positive blood donors. J Viral Hepat 2012; 19: 867-71.

  28. Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, McHutchinson JP, et al. The course of posttransplant hepatitis c infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 2012; 94: 197-203.

  29. Cisneros E, Baños I, Citores MJ, Duca A, Salas C, Noblejas A, Cañizares M, et al. Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860. Transplantation 2012; 94(3): 275-80.

  30. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, Heimbach JK, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-24.

  31. Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-Tapias JM, Martorell J, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11: 1051-7.

  32. Lange CM, Moradpour D, Doehring A, Lehr HA, Müllhaupt B, Bibert S, Bochud PY, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55: 322-7.

  33. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.

  34. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.

  35. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012; 18: 1053-9.

  36. Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012; 32(Suppl. 1): 120-8.

  37. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Short report: Telaprevir-based triple therapy in liver transplanted HCV patients: A 12 week pilot study providing safety and efficacy. Liver Transpl 2012; 18: 1464-70.

  38. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et al. Safety and Efficacy of Protease Inhibitors to Treat Hepatitis C After Liver Transplantation, a Multicenter Experience. J Hepatol 2014; 60: 78-86.




2020     |     www.medigraphic.com